Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -9,267.68%.

  • Dianthus Therapeutics' EBITDA Margin fell 814171.00% to -9,267.68% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,121.60%, marking a year-over-year decrease of 287686.00%. This contributed to the annual value of -1,361.83% for FY2024, which is 17204.00% up from last year.
  • Per Dianthus Therapeutics' latest filing, its EBITDA Margin stood at -9,267.68% for Q3 2025, which was up 43.75% from -16,477.20% recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' EBITDA Margin peaked at -676.39% during Q3 2022, and registered a low of -16,477.20% during Q2 2025.
  • Its 3-year average for EBITDA Margin is -3,698.22%, with a median of -1,596.10% in 2023.
  • In the last 5 years, Dianthus Therapeutics' EBITDA Margin skyrocketed by 47,014bps in 2024 and then slumped by 1,553,158bps in 2025.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' EBITDA Margin stood at -861.87% in 2022, then crashed by 160,573bps to -2,467.61% in 2023, then surged by 27,945bps to -2,188.16% in 2024, then slumped by 814,171bps to -9,267.68% in 2025.
  • Its EBITDA Margin was -9,267.68% in Q3 2025, compared to -16,477.20% in Q2 2025 and -2,523.39% in Q1 2025.